Bristol-Myers Squibb
BMY
A$71.22
Share price
-1.98%
Change (1 day)
19.97%
Change (1 year)
Categories
Market capitalization of Bristol-Myers Squibb (BMY)
Market cap: A$144.93 Billion
As of July 2025 Bristol-Myers Squibb has a market cap of A$144.93 Billion. This makes Bristol-Myers Squibb the world's 210th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Bristol-Myers Squibb from 1996 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | A$144.93 B | -22.94% |
| 2024 | A$188.07 B | 22.73% |
| 2023 | A$153.24 B | -31.83% |
| 2022 | A$224.80 B | 17.76% |
| 2021 | A$190.89 B | 4.72% |
| 2020 | A$182.29 B | -10.76% |
| 2019 | A$204.26 B | 70.47% |
| 2018 | A$119.82 B | -6.73% |
| 2017 | A$128.47 B | -5.18% |
| 2016 | A$135.49 B | -13.61% |
| 2015 | A$156.84 B | 31.55% |
| 2014 | A$119.22 B | 21.93% |
| 2013 | A$97.78 B | 91.29% |
| 2012 | A$51.11 B | -12.23% |
| 2011 | A$58.23 B | 31.49% |
| 2010 | A$44.29 B | -7.8% |
| 2009 | A$48.03 B | -26.37% |
| 2008 | A$65.23 B | 8.95% |
| 2007 | A$59.87 B | -8.59% |
| 2006 | A$65.50 B | 6.58% |
| 2005 | A$61.46 B | -4.65% |
| 2004 | A$64.45 B | -13.64% |
| 2003 | A$74.64 B | -7.01% |
| 2002 | A$80.27 B | -59.06% |
| 2001 | A$196.08 B | -24.1% |
| 2000 | A$258.33 B | 33.52% |
| 1999 | A$193.48 B | -10.96% |
| 1998 | A$217.31 B | 50.65% |
| 1997 | A$144.25 B | 110.12% |
| 1996 | A$68.65 B |
End of Day market cap according to different sources
On Jul 14th, 2025 the market cap of Bristol-Myers Squibb was reported to be:
A$147.85 Billion
A$147.85 Billion
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | A$214.46 B | 47.98% | 🇺🇸 USA |
 Merck MRK | A$314.76 B | 117.18% | 🇺🇸 USA |
 Eli Lilly LLY | A$1.060 T | 631.71% | 🇺🇸 USA |
 Novartis NVS | A$363.37 B | 150.72% | 🇨🇭 Switzerland |
 Sanofi SNY | A$179.74 B | 24.02% | 🇫🇷 France |
 AstraZeneca AZN | A$334.95 B | 131.11% | 🇬🇧 UK |
 Johnson & Johnson JNJ | A$573.49 B | 295.70% | 🇺🇸 USA |
 AbbVie ABBV | A$505.37 B | 248.70% | 🇺🇸 USA |
 Amgen AMGN | A$241.58 B | 66.69% | 🇺🇸 USA |
 Biogen BIIB | A$28.88 B | -80.07% | 🇺🇸 USA |